Search Results
Your search for The matches 34618 pages
Showing 21251 - 21300Expert Point of Review: Amrita Krishnan, MD
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope in Duarte, California, told The ASCO Post that the most exciting drug in the “New Agents” session she moderated at the 2016 American Society of Hematology (ASH) Annual Meeting...
Two Studies Show Potential of Venetoclax as Single Agent and in Combination for Myeloma
Early-phase studies suggest that venetoclax (Venclexta) holds promise as a treatment for myeloma. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, investigators reported strong activity in heavily pretreated patients, especially those with the t(11;14)...
FNIH Awards Lurie Prize in Biomedical Sciences to David M. Sabatini, MD, PhD
The Foundation for the National Institutes of Health (FNIH) has selected David M. Sabatini, MD, PhD, to receive its 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to...
ASCO Selects 2017–2018 Health Policy Fellows
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its second year. The fellowship, aimed at early career oncologists, provides the skills necessary to monitor and shape the regulatory and ...
Different Subtypes of Acute Myeloid Leukemia Create Both Clinical and Research Challenges
Acute myeloid leukemia (AML) is the most common leukemia in adults. Each year, about 20,000 Americans will be diagnosed with AML, and roughly 10,000 people in this country will die of the disease. AML progresses quickly, and unless treatment begins soon and is effective , the prognosis is grim....
Cranberry
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time....
Study Finds Link Between Telomere Length and Sociodemographic Circumstances Linked to Neighborhood
Researchers at Fox Chase Cancer Center have begun to establish a biologic basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Program at Fox Chase, led a team...
Roswell Park Names Chair of Cancer Genetics and Genomics
John Krolewski, MD, PhD, has been appointed as Chair of the Department of Cancer Genetics and Genomics and Co-Leader of the Cancer Center Support Grant (CCSG) Genetics and Genomics Program at Roswell Park Cancer Institute. He will also hold the John & Santa Palisano Endowed Chair of Cancer...
Paula H. Finestone, PhD, Joins Fox Chase Cancer Center
Fox Chase Cancer Center has announced the hiring of Paula H. Finestone, PhD, a psychologist who has joined the Center’s Department of Medicine. Before arriving at Fox Chase, Dr. Finestone was a clinical psychologist at Bryn Mawr Rehab, where she worked with inpatients and outpatients facing...
Kristy L. Weber, MD, Named Second Vice President, AAOS Board of Directors
Orthopedic surgeon Kristy L. Weber, MD, became the second Vice President of the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors at the organization’s 2017 Annual Meeting. Her new role is the first position in a 4-year term of volunteer service that includes Dr. Weber serving as...
Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer
Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...
Joanne Berger-Sweeney, PhD, MPH, Elected to Cold Spring Harbor Laboratory Board of Trustees
Cold Spring Harbor Laboratory has announced the election of Joanne Berger-Sweeney, PhD, MPH, President of Trinity College, to its Board of Trustees. “We are pleased to welcome Dr. Berger-Sweeney to the board of Cold Spring Harbor Laboratory. Her leadership at premier academic institutions in the...
New Study Finds Global Smoking Rates on Decline but Shows More Work Is Still Needed
On March 21, 2017, Gravely et al published a study1 in Lancet Public Health on the 2003 global tobacco control treaty’s impact on the adoption of tobacco-reduction measures around the world, which has led to a 2.5% reduction in global smoking rates. The treaty obligates the 180 countries committed...
Research Reveals New Treatment Possibilities for Prostate Cancer
Not all cancer research will result in a positive outcome for patients, but all research does provide information that continues to advance the treatment of cancer care. Recent clinical trials, including one funded in part by the Conquer Cancer Foundation (CCF) of ASCO, show that most prostate...
Conquer Cancer Foundation Recognizes Global Oncology Researchers With International Innovation Grant
The Conquer Cancer Foundation (CCF) of ASCO recently announced the recipients of its 2017 International Innovation Grant. The 1-year grant of up to $20,000, given directly to each awardee’s nonprofit organization or government agency, funds research projects aimed at improving cancer care in low-...
Pembrolizumab Active in Mucosal Melanoma in KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO).1 Mucosal melanoma has often been excluded from...
New ASCO Answers Managing Cancer-Related Pain Booklet for Your Patients
In this new booklet, patients and their caregivers explore the topic of cancer-related pain relief, including its causes, how it is diagnosed, and types of relief strategies. Pain medications are covered extensively, including: Types of medications Safe handling Common concerns Managing...
Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach, in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA).1 Together, stomach and esophageal cancers...
MACRA Implementation Has Begun: Will You Avoid a 4% Reimbursement Penalty?
As most oncology professionals know, the Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), began on January 1, 2017—but did you know that 2017 is a transition year, meaning you can “Pick Your Pace” when implementing QPP in your practice? “Pick...
Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer
The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress (Abstract 540).1 Study Design and Key Findings...
Expert Point of View: Jonathan Ledermann, MD
Invited discussant Jonathan Ledermann, MD, of UCL Cancer Institute, University College London, said the ARIEL2 results for rucaparib (Rubraca) add to the evidence base for PARP (poly ADP-ribose polymerase) inhibition in ovarian cancer established by olaparib (Lynparza). It’s been about 2 years...
Rucaparib Leads to Frequent Durable Remissions in BRCA-Mutated Relapsed Ovarian Cancer
Rucaparib (Rubraca) led to frequent durable remissions among patients with relapsed high-grade ovarian cancer with BRCA mutations, regardless of whether the mutations were germline or somatic, according to the results of the ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual...
ASCO Honors Researchers, Scientists for Significant Advances in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation (CCF) proudly announce the winners of ASCO’s Special Awards, the Society’s highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked ...
James Mohler, MD, Receives 2017 Rodger Winn Award
An accomplished urologic oncologist and longtime senior leader at Roswell Park Cancer Institute, James Mohler, MD, received the 2017 Rodger Winn Award at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference in Orlando, Florida. Dr. Mohler is Associate Director and Senior Vice...
Featured Lectures Presented at Society of Surgical Oncology
James Ewing Lecture: Jedd D. Wolchok, MD, PhD, presented the 2017 James Ewing Lecture on “Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms.” Dr. Wolchok is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics...
Can You Hear Me Now? Listening to the Cancer Patient
At this year’s ASCO Quality Care Symposium, Neeraj K. Arora, PhD, Associate Director at the Patient-Centered Outcomes Research Institute, opened his presentation by stressing that integrating the patient’s voice and experience into the clinical setting produces better health outcomes.1 Dr. Arora,...
Expert Point of View: Steven L. Chen, MD
“Dr. Neuman and colleagues point out that patients often will seek out information on their diagnosis preconsultation,” commented session co-moderator Steven L. Chen, MD, a surgical oncologist with OasisMD in San Diego. “Their study demonstrates that the provision of high-quality information can...
Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options
A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...
An Oncology Care Model: One Institute’s Experience
At this year’s ASCO Quality Care Symposium, Blase N. Polite, MD, MPP, Associate Professor of Medicine at The University of Chicago Medical Center, examined his practice’s experience with the Oncology Care Model, a Centers for Medicare & Medicaid Services test payment and delivery program...
FDA Permits Marketing for Digital Pathology Solution for Primary Diagnostic Use
The U.S. Food and Drug Administration (FDA) has permitted marketing of the Philips IntelliSite Pathology Solution (PIPS, Philips Medical Systems Nederland B.V.), as an aid to pathologists to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin...
Expert Point of View: Kelly M. McMasters, MD, PhD
“Several gene-expression profiles have been evaluated to predict prognosis in colorectal cancer, but none have become widely accepted or U.S. Food and Drug Administration–approved. This has important implications for deciding which patients may benefit from adjuvant chemotherapy,” commented...
Machine Learning Model Predicts Colorectal Cancer Recurrence
A machine learning model that uses a set or ensemble of algorithms has good accuracy for predicting colorectal cancer recurrence, investigators reported during a plenary session at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 Persistent key questions in managing early...
FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers
On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was previously approved for people...
ASCO Releases Position Statement on Access to Investigational Drugs
ASCO strongly supports increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed federal “right-to-try” legislation as well as state-enacted right-to-try laws. In a position statement released April 4, 2017, ASCO said ...
Expert Point of View: Suzanne L. Topalian, MD
“Avelumab (Bavencio) is the very first drug approved for Merkel cell carcinoma, an orphan disease that is uncommon in the United States. For that reason, pharmacologic development has been slow. In this case, laboratory evidence provided a rationale for testing checkpoint inhibitors in Merkel cell ...
Avelumab Produces Durable Responses in Merkel Cell Carcinoma, Becomes First Drug Approved for the Rare Disease
Avelumab (Bavencio) achieved durable responses in patients with metastatic Merkel cell carcinoma, according to longer-term follow-up of the phase II JAVELIN study, the largest study conducted to date in this relatively rare orphan cancer.1 Results were presented at the 2017 American Association for ...
Deintensifiying Treatment of HPV-Positive Oropharyngeal Cancer Could Reduce Toxicity While Maintaining Function and Survival
“The status quo for HPV [human papillomavirus]-associated oropharyngeal squamous cell carcinoma is not sufficient.… Our treatment is effective, but the toxicity associated with it is not tolerable.” And HPV-associated oropharyngeal cancer “is a cancer of relatively younger patients,” said Nishant...
W.E. ‘Ed’ Bosarge, Jr, PhD, Honored With 2017 AACR Distinguished Public Service Award
The American Association for Cancer Research (AACR) presented an AACR Distinguished Public Service Award to W.E. “Ed” Bosarge, Jr, PhD, in honor of his generous, unstinting contributions to cancer research, innovative medical and environmental science, and the AACR. Dr. Bosarge is known for his...
Mark S. Soberman, MD, MBA, FACS, Named ACCC President
Mark S. Soberman, MD, MBA, FACS, was elected as the 2017–2018 President of the Association of Community Cancer Centers (ACCC) during its 43rd Annual Meeting on March 31, 2017, in Washington, DC. Dr. Soberman brings a wealth of experience in thoracic surgery, thoracic oncology, and value-based...
Medical Groups Unite in Support of March for Science
Twenty-five of the nation’s leading medical groups issued this statement on April 17: As the world's leading organizations representing clinicians, laboratory researchers, and physician-scientists committed to improving patient care, we support the March for Science and its nonpartisan call...
Resilience Linked to Less Distress in Lesbian and Bisexual Breast Cancer Survivors
Breast cancer can have a pervasive effect on a woman’s psychological functioning, but sexual minority (ie, lesbian and bisexual) breast cancer survivors are underrepresented in studies of psychological distress, according to Charles Kamen, PhD, a clinical psychologist at the University of Rochester ...
Next-Generation Genitourinary Oncology: Keeping One’s Powder Dry
There is a new yin-yang of management in genitourinary oncology, with the balance of opposing power focused among cancer cells, kinase inhibition, and lymphocyte function, representing a shift in the fashions of treatment somewhat away from chemotherapy. This linear progress has been complicated...
Attrition High but Positive Trends Observed in Web-Based Intervention Addressing Caregiver Burden
High attrition but positive trends such as increased “benefit finding” were observed with a Web-based intervention designed to address the psychosocial burden on informal caregivers, according to Allison J. Applebaum, PhD, a licensed clinical psychologist at Memorial Sloan Kettering Cancer Center...
How ASCO’s CancerLinQ Discovery™ Will Help Speed Research Advances and Improve Patient Outcomes
This past November, ASCO announced the launch of CancerLinQ Discovery™, a big data learning platform physicians and researchers can use to analyze highly curated, de-identified, real-world cancer care data sets to broaden their clinical knowledge about specific cancers and eventually improve...
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the management of oropharyngeal cancer. The guideline, “Radiation therapy for oropharyngeal squamous cell carcinoma: An ASTRO Evidence-based Clinical Practice Guideline,” was published by Sher et ...
AACR Introduces New Incoming Officers of the Associate Member Council
The American Association for Cancer Research (AACR) issued congratulations to Allison S. Betof, MD, PhD, on her election to Chairperson-elect of the Associate Member Council (AMC) of AACR. Dr. Betof assumed office at the AACR Annual Meeting earlier this month and will serve as Chairperson-elect...
Expert Point of View: Rodrigo Dienstmann, MD
“This is one of the most beautiful stories we have in translational precision oncology research in colorectal cancer. We have robust preclinical data, rigorous molecular diagnosis, and successful clinical results,” said formal discussant of this trial, Rodrigo Dienstmann, MD, of Vall D’Hebron...
Conditional Survival After Initial Diagnosis and Treatment of Stage III Melanoma
In an Australian study reported in the Journal of Clinical Oncology, Haydu et al found that conditional melanoma-specific survival was worse within the first 2 years of diagnosis of stage III disease for men, increasing age, and increasing American Joint Committee on Cancer (AJCC) stage. The...
Effect of Radiotherapy Boost for Ductal Carcinoma in Situ After Whole-Breast Radiotherapy
In an analysis reported in JAMA Oncology, Moran et al found that a radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy was associated with a reduction in the risk for ipsilateral breast tumor recurrence. Study Details The analysis pooled...
Dual HER2 Targeting of HER2-Positive Metastatic Colorectal Cancer Shows Clinical Benefit
The combination of trastuzumab (Herceptin) plus lapatinib (Tykerb) achieved positive results in patients with heavily pretreated, HER2-positive metastatic colorectal cancer, according to the final results of the phase II HERACLES-A trial. This two-pronged, HER2-directed approach achieved clinical...
